PROTEASE-ACTIVATED RECEPTOR 2 (PAR-2) A NOVEL TARGET TO PREVENT FIX INHIBITOR FORMATION
Abstract number: P-W-222
Baila1 S., Furlan Freguia2 C., Favaro2 P., Schuettrumpf2 J., Mingozzi2 F., Andrade-Gordon3 P., Arruda2 V.
11Pediatric, Children Hospital of Philadelphia 22Pediatric, Children'sHospital of Philadelphia, Philadelphia 33R&D, Johnson and Johnson Pharmaceutical, Spring House, United States
How-to-cite Baila S, Furlan Freguia C, Favaro P, Schuettrumpf J, Mingozzi F, Andrade-Gordon P, Arruda V. PROTEASE-ACTIVATED RECEPTOR 2 (PAR-2) A NOVEL TARGET TO PREVENT FIX INHIBITOR FORMATION. J Thromb Haemost 2007; 5 Supplement 2: P-W-222
Introduction: Intramuscular injection (IM) of adeno-associated viral (AAV) is a promising therapeutic strategy for the treatment of hemophilia B. AAV serotype 1 (AAV-1) resulted in high level of transgene expression but the immune response to the transgene is a major complication. We sought to determine whether inhibition of PARs, which modulate inflammatory and immune responses, could prevent immune responses to the FIX following IM injection of AAV1-FIX.
Methods: We used three animal models. PAR-1 and PAR-2 knockout (-/-) mice were generated on C57Bl/6 background. In addition, hemophilia B mice were also crossed to PAR-2 (-/-) mice. Experiments were carried out by comparing littermate mice. AAV-1 vector encoding human FIX under the control of a CMV promoter were delivered at 2 IM sites. We monitored circulating FIX antigen and formation of antibody to the transgene by both an specific-ELISA IgG and neutralizing assay (Bethesda assay).
Results: PAR-1 and PAR-2 (-/-) mice received IM injections of AAV1-hFIX at doses range from 5×1011 to 1×1012vg/kg and inhibitor were monitored by Bethesda assay (BU) and ELISA (IgG-FIX). PAR-2 (-/-) mice did not develop inhibitory antibodies (0/12), whereas, 70% (10-14) of the PAR-2 (+/+)/(+/-) mice developed FIX inhibitor (BU up to 3.6) In contrast, at similar vector doses, the absence of PAR-1 did not prevent antibodies formation. PAR-2 (-/-) developed tolerance to FIX and no inhibitor to the protein was detected upon repetitive exposure to FIX-CFA and no INF-gamma was secreted from splenocytes harvest from these animals. In addition, hemophilia B mice crossed with PAR-2 (-/-) challenged with FIX protein presented a delay in the formation of antibody compared to littermates controls.
Conclusions: The data suggest a role of PARs in the immune response to FIX. Inhibition of PAR-2 (but not PAR-1) could be a novel target in preventing inhibitor formation in hemophilia gene therapy.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
||XXIst ISTH Congress
| Back to top